Search Results 621-630 of 18033 for Alopecia

1. A Study of Nivolumab and Multi-fraction Stereotactic Radiosurgery with or without Ipilimumab in Treating Participants with Recurrent Grade II-III Meningioma - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory ...

2. LC-MS/MS lowers diagnostic thresholds for androgen-producing tumors or pathological hyperandrogenism in women - Mayo Clinic

   52 (58%) women were diagnosed with polycystic ovary syndrome (PCOS). Women with APT were more likely to have male-pattern alopecia documented on physical ...

3. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Adverse effect of prior therapy not resolved to CTCAE Grade 1 or below with the exception of alopecia. Ongoing Grade 2 non-hematologic toxicity related to ...

4. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.

5. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

6. Amg 510 (Sotorasib) With Or Without Panitumumab In Advanced Solid Tumors: A Combomatch Treatment Trial - Mayo Clinic

   Patients must have recovered to CTCAE Grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia). Patient must ...

7. Long-term Safety and Effectiveness Study for Participants with Advanced Tumors who are Currently on Treatment or in Follow-up in a Pembrolizumab Trial - Mayo Clinic

   alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of >30 Gray (Gy), they must ...

8. A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) - Mayo Clinic

   Toxicity from prior therapies recovered to Grade ≤ 1 or subject's baseline, except for alopecia. In addition, endocrinopathies associated with prior ...

9. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

   03) > Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia. Any grade of neuropathy from any cause. Any prior oxaliplatin ...

10. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer - Mayo Clinic

    o Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo,psoriasis or alopecia) not ...